The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2023 | Treatment intensity in frail patients with newly diagnosed multiple myeloma: VRd vs Rd
Clark DuMontier, MD, MPH, VA Boston Healthcare System, Brigham and Women’s Hospital/Harvard Medical School, Boston, MA, discusses a real-world retrospective study comparing the less intense treatment regimen lenalidomide-dexamethasone (Rd) to the more intense triplet bortezomib-lenalidomide-dexamethasone (VRd) in elderly, frail patients with newly diagnosed multiple myeloma (NDMM). The findings confirm the benefit of VRd over Rd in moderate-severely frail patients, challenging the conventional view that frail patients should receive less intense treatment regimens. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
